Biosimilar medicine

generic copies of off patent biologic drugs that are similar but not exact copies of the original therapy

Developing biosimilar monoclonal antibodies will not be easy

Wednesday 23 March 2011

Interviewee/Contributer: Gabriele Schaffner-Dallmann

Organisation: Pharmatching GmbH

Full text available to subscribers only. Click here for information on subscribing to MedNous.

EMA guidance on biosimilar monoclonal antibodies

Wednesday 12 January 2011

Interviewee/Contributer: Cecil Nick

Organisation: Parexel

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Syndicate content